Non-Hodgkin's Lymphomas of the Tonsil: A Retrospective Analysis of Twenty-Eight Patients with Primary Tonsillary Lymphoma

1995 ◽  
Vol 81 (4) ◽  
pp. 234-237 ◽  
Author(s):  
İbrahim Barışta ◽  
Gülten Tekuzman ◽  
İbrahim Güllü ◽  
Eşmen Baltalı ◽  
Ayşe Kars ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Important Prognostic Factor ◽  
Non Hodgkin’S Lymphoma ◽  
Combined Modality ◽  
Non Hodgkin's Lymphoma ◽  
Radiotherapy Alone ◽  
Poorly Differentiated ◽  
Hodgkin's Lymphomas

Aims To analyze the clinical and therapeutic aspects of patients with primary tonsillary non-Hodgkin's lymphoma. Methods Twenty-eight patients with primary tonsillary non-Hodgkin's lymphoma who had been followed in the Hacettepe Oncology Institute between 1974 and 1992 were retrospectively analyzed. Fifteen patients were male, 13 were female. Median age was 55 years. Results Constitutional symptoms were present in 10 patients (35.7%). Stages according to the Ann Arbor classification were I and II in 12 and 16 patients, respectively. According to the Rappaport classification, poorly differentiated lymphocytic was the most common pathologic subgroup (42.9%). Grades according to the Working Formulation were low, intermediate and high in 3, 22 and 3 patients, respectively. Twenty-two patients had received chemotherapy. Cyclophosphamide, vincristine and prednisone (CVP), and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) were the regimens most commonly employed. Eighteen patients received radiotherapy to Waldeyer's ring and neck. Eight patients achieved remission with chemotherapy plus radiotherapy, 7 patients with chemotherapy alone, and 5 patients with radiotherapy alone. In addition to the 20 patients who achieved complete remission, 3 patients achieved partial remission; the overall response rate was 82.1%. The response rates and survival attained with the combined modality, chemotherapy, or radiotherapy alone were not statistically different (P > 0.05). The median follow-up was 14 months. Overall and disease-free survival at 5 years were 62.6% and 77.6%, respectively. Pathologic grade was the most important prognostic factor influencing overall survival in the Cox multivariate model. Conclusions Poorly differentiated lymphocytic lymphomas were the most common pathologic subtype, and pathologic grade was the most important prognostic factor to influence survival in the present study. Although combined modality treatment did not appear to be superior to chemotherapy or radiotherapy alone, a larger number of patients is needed to draw definite conclusions.

scholarly journals Primary Non-Hodgkin's Lymphoma involving Parotid Gland: A Rare Entity

2017 ◽  
Vol 7 (1) ◽  
pp. 71-75
Author(s):  
Sushrut Vaidya ◽  
Srivalli Natrajan ◽  
Sneha Kadam
Keyword(s):  
Parotid Gland ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Resected Specimen ◽  
Rare Entity ◽  
Primary Tumors ◽  
Nerve Preservation ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Hodgkin's Lymphomas

ABSTRACT Non-Hodgkin's lymphomas constitute 25 to 40% of all lymphomas. The gastrointestinal tract is the most common site followed by the head and neck area. Salivary gland involvement is a very rare entity and is involved in 0.5 to 5% of all cases. Among all the major salivary glands, the parotid gland is commonly involved followed by the submandibular glands. Misdiagnosis often leads to unnecessary diagnostic procedures, which leads to delay in initiation of appropriate treatment. It is often difficult to diagnose the distinction between lymphoma developing primarily in the parotid gland tissue and in the intraparotid lymph nodes. As per the reports, primary tumors of the parotid gland show no characteristic features on diagnostic imaging, reflecting none of their histological findings. We represent a case of a 61-year-old female who presented with painless, gradually increasing mass in the right parotid region. Imaging studies were suggestive of an infiltrative mass lesion involving right the parotid gland. The patient underwent superficial parotidectomy along with the excision of the part of the deep lobe posterior to submandibular gland with facial nerve preservation. Histopathology of the resected specimen shows infiltrates of lymphocytes into the glandular parenchyma destroying its normal lobular organization and disrupting the normal glandular architecture. How to cite this article Vaidya S, Natrajan S, Kadam S. Primary Non-Hodgkin's Lymphoma involving Parotid Gland: A Rare Entity. J Contemp Dent 2017;7(1):71-75.

T- Cell Non-Hodgkin's Lymphoma, Data From a Mexican Tertiary Health Center..

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 5030-5030
Author(s):  
Silvia Rivas-Vera ◽  
Mabel Oropeza-Borges ◽  
Pedro Sobrevilla-Calvo
Keyword(s):  
T Cell ◽  
Health Center ◽  
Hodgkin’S Lymphoma ◽  
Prognostic Index ◽  
Hodgkin's Lymphoma ◽  
Anaplastic Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
T Cell Lymphomas ◽  
Non Hodgkin's Lymphoma ◽  
Hodgkin's Lymphomas

Abstract Abstract 5030 Introduction T cell Non/Hodgkin's lymphomas (TCNHL) are a group of lymphomas characterized by an aggressive clinical course and resistance to the usual chemotherapy agents. Due to the limited availability of immunochemistry techniques the frequency and clinical presentation of these lymphomas are not well described in underdeveloped countries. Here we describe the experience with these diseases in a tertiary referral health center. Patients and methods We reviewed 520 cases with diagnosis of Non-Hodgkin's Lymphoma from the records of the Pathology Department of the Hospital General de Mexico, seen from January 2002 to July 2006. Results We found 80 cases with TCNHL (15.3%). In 62 cases the clinical information was available for review. We found a 1.45:1 male/female ratio, median age 32 years (range 17 to 83). Symptoms were present for a median of 6 months (range 1 to 120 months) before diagnosis. Regarding the pathological classification the Unspecified Peripheral T-cell lymphomas were more common (56%), followed by the anaplastic lymphoma (23%), T/NK (16%), Cutaneous lymphoma (3%) and angioimmunoblastic lymphoma (2%). In 56% the initial presentation was nodal and in 44% extranodal. The extranodal sites were: Nasal (34%), bone marrow (22%), pleura and lung (14%), parotid (5%), colon (5%), and liver (5%). Sixty seven percent of the patients had advanced clinical stages and 73% had at least 3 B symptoms. One quarter of patients had bulky disease at their first visit to our Hospital; the most frequent site was retroperitoneal (19%). The lactic dehydrogenase (LDH) was elevated in 89% of cases (range:97 U/L -3017 IU L, median 418 U/L); patients with anaplastic NHL had the highest values and NHL-TNK patients the lowest. HIV serology was performed in 41 of 62 patients. Ninety four percent of the patients had an ECOG between 1 and 3. We calculated the International Prognostic Index (IPI); it was low in 23 patients (37%), low-intermediate in 18 (29%), intermediate-high in 16 (26%) and high in just 5 patients (8%). When we classified the patients with the Prognostic Index for non-specific peripheral T-NHL (PIT or PTCL-L), we found that 79.4% of cases were in the high-risk group in contrast with 73.6% low group according to IPI. All patients were treated with CHOP chemotherapy. A complete response (CR) was achieved in 10 patients (16%); 13 patients (21%) were still on treatment at the end of the study, 4 patients (6.45%) did not respond to treatment and 14 patients (24.1%) had progressive disease. Ten patients discontinued treatment (16%) and 5 died (8.06%). At the end of the observation period 8 patients were alive without tumor activity, 2 patients were lost without tumor activity, 7 patients were alive with disease, 24 patients were missing with tumor activity, 9 patients were on treatment and 12 patients had died. Conclusions This study shows that in Mexico as in other populations, the TCNHL are less frequent than the B-cell lymphomas. It also confirms the poor response of the T-Cell lymphomas to CHOP. The population that attends our hospital is of a low socioeconomic stratum, and this fact explains the large abandonment of medical care. It is desirable the development of new drugs for these neoplasia. Disclosures No relevant conflicts of interest to declare.

scholarly journals AgNORs as Prognostic Factor of Gastric Non-Hodgkin's Lymphoma.

1994 ◽  
Vol 27 (12) ◽  
pp. 2523-2529
Author(s):  
Junichi Hasegawa ◽  
Kazuyasu Nakao ◽  
Masaaki Nakahara ◽  
Nobuo Ogino ◽  
Toshirou Nishida ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients

Blood ◽  
1983 ◽  
Vol 62 (1) ◽  
pp. 51-61 ◽  
Author(s):  
KM Sullivan ◽  
PE Neiman ◽  
ME Kadin ◽  
S Dahlberg ◽  
VT Farewell ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Stage Iv ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Combined Modality Treatment ◽  
Mixed Cell ◽  
Remission Duration ◽  
Non Hodgkin’S Lymphoma ◽  
Combined Modality ◽  
Non Hodgkin's Lymphoma

Abstract Ninety-five patients with advanced non-Hodgkin's lymphoma were treated with four courses of cyclophosphamide, adriamycin, vincristine and prednisone, with or without procarbazine [CHOP(P)] chemotherapy; either 150 rad total body irradiation (for “extensive” disease) or 3,500 rad local radiation therapy (for “limited” disease); and a final four courses of CHOP(P) chemotherapy. Sixty-four patients had stage IV, 22 stage III, and 9 abdominal stage II disease. Histologic material was available in 80 patients for review according to the new Working Formulation: 16 had low grade, 38 intermediate grade (20 large cell, 18 diffuse small cleaved and mixed cell), and 26 high grade (12 lymphoblastic, 8 immunoblastic, 6 small noncleaved) malignancies. Complete remission was achieved in 78% of 92 evaluable patients. The remission duration curve for diffuse large cell lymphoma patients showed a plateau at 72% after 2 yr, but a pattern of continued relapse (median 3 yr) was seen in the other histologies. Multivariate analysis showed that “B” symptoms, bulky abdominal masses, and stage IV disease adversely affected survival. Overall survival by Kaplan-Meier analysis showed that 67% of diffuse small cleaved and mixed cell, 49% of large cell and immunoblastic, and 44% of lymphoblastic lymphoma patients survive 6 yr after diagnosis. When compared to reported remission duration and survival with CHOP chemotherapy alone, these data suggest a possible advantage for combined modality treatment.

Sign in / Sign up

Export Citation Format

Share Document